A company that helps discover new drugs has acquired the 海角视频’s biggest lab-based clinical research organisation.
Sygnature Discovery has bought XenoGesis. Both are leaders in their fields and are based at the Biocity complex in Nottingham.
In recent years Sygnature has been broadening its drug discovery offering through the addition of two other clinical research organisations – RenaSci and Alderley Oncology.
READ MORE: {}
The latest deal will both help it meet an increasing demand for its services and boost the reach of its pre-clinical work.
XenoGesis was launched in 2011 and focuses on looking at the way drugs move through the body and working out likely human dosages.
The acquisition effectively doubles the size of Sygnature’s drug safety evaluation work, which began in 2015, broadening its discovery and development expertise, complementing its existing service-offering and adding new skills and capabilities.
Sygnature Discovery founder and chief executive Dr Simon Hirst said: “Our ultimate mission at Sygnature is to help create life-changing drugs for patients that have made it through the drug discovery and development process, and we recognise the central role that DMPK plays in that journey.
“Sygnature is not growing for the sake of growing.
Most Read
“We believe that truly integrated drug discovery is the best possible way forward in bringing novel efficacious drug candidates to man; that having teams working together across every discipline involved in a research project, sharing ideas and resolving challenges, will produce the sparks of innovation and high-quality science needed to enable success.
“We have always had tremendous respect for the work that XenoGesis does, and have a strong history of collaboration with them over the years.
“We are thrilled at this opportunity to build on the capabilities of both companies and enrich our service-offering going forward together.”
Dr Richard Weaver, CEO and founder of XenoGesis said: “Sygnature and XenoGesis have always had a superb working relationship and been closely aligned in our culture and aspirations.
“From the start, both companies have focused on world-class science, insightful data interpretation, and creating genuine partnerships with our customers.
“Therefore, this step feels like a very natural one, and we are very excited about what we can accomplish together in helping accelerate our customers’ projects towards the clinic.
“My team and I are looking forward to joining forces with Sygnature.”